While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that leverages its financial strength to beat its competitors and two that may struggle to keep up.
Two Stocks to Sell:
Energy Recovery (ERII)
Trailing 12-Month Free Cash Flow Margin: 12.9%
Having saved far more than a trillion gallons of water, Energy Recovery (NASDAQ: ERII) provides energy recovery devices to the water treatment, oil and gas, and chemical processing sectors.
Why Are We Cautious About ERII?
- Annual revenue growth of 2.6% over the last two years was below our standards for the industrials sector
- Estimated sales decline of 12.7% for the next 12 months implies a challenging demand environment
- Diminishing returns on capital suggest its earlier profit pools are drying up
Energy Recovery is trading at $11.03 per share, or 16.7x forward P/E. Check out our free in-depth research report to learn more about why ERII doesn’t pass our bar.
LifeStance Health Group (LFST)
Trailing 12-Month Free Cash Flow Margin: 7.7%
With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ: LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.
Why Do We Think Twice About LFST?
- Modest revenue base of $1.42 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Push for growth has led to negative returns on capital, signaling value destruction
LifeStance Health Group’s stock price of $7.00 implies a valuation ratio of 23.3x forward P/E. To fully understand why you should be careful with LFST, check out our full research report (it’s free).
One Stock to Buy:
DexCom (DXCM)
Trailing 12-Month Free Cash Flow Margin: 23.1%
Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ: DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.
Why Is DXCM a Top Pick?
- Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 14.1% over the past two years
- Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
- Free cash flow margin grew by 20.9 percentage points over the last five years, giving the company more chips to play with
At $62.39 per share, DexCom trades at 25.5x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
